Daewoong Co., Ltd.
KKRX:00309014,950.00
KRW
-50.00
(-0.33%)
ISIN
KR7003090008
Return %
Stock
S&P 500
1Y
-31.42
14.39
3Y
-1.84
81.42
5Y
-54.56
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jae-Chun Yoon
- Full Time Employees
- 413
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 244 Galmachi-ro Seongnam-si GY South Korea
- IPO Date
- Jun 26, 1973
- Website
- daewoongholdings.com
- Similar Companies
- Business
- Daewoong Co., Ltd. engages primarily in the research, development, manufacturing, and sale of pharmaceutical products, serving both domestic and international markets. The company's product portfolio includes biologics, chemical pharmaceuticals, new drugs, biosimilars, stem cell therapies, antibiotics, enzymes, medical devices, and finished dosage forms. Daewoong markets specialty and generic pharmaceuticals across therapeutic areas including chronic, autoimmune, and orphan diseases. The company also provides contract manufacturing organization (CMO) services and operates a division for real estate rental and lifestyle-related disease prevention research. Headquartered in Seongnam, South Korea, Daewoong was founded in 1945 and has expanded its global footprint with branch offices and research centers in the United States, China, India, and throughout Asia. In recent developments over the last 1-2 years, Daewoong has significantly enhanced its strategic partnerships and research collaborations globally. Notably, it entered a research collaboration with Swedish biotech firm Salipro Biotech in 2025 to advance novel therapeutics using Salipro’s proprietary technology. It strengthened its strategic partnership with M8 Pharmaceuticals to commercialize diabetes treatment Envlo™ in Latin America. Daewoong has been expanding its product offerings in the aesthetic medicine sector through launching Total K-Aesthetic Solutions in markets like Indonesia, integrating botulinum toxins, hyaluronic acid fillers, and thread lifting products. Additionally, Daewoong Bio opened a Bio-Center in South Korea to provide integrated CMO services, reinforcing the company’s contract manufacturing capabilities. These moves complement Daewoong’s ongoing emphasis on innovative new drug development, global expansion, and enhanced manufacturing capacity under cGMP guidelines. Daewoong operates mainly within the pharmaceutical and healthcare industry segments, targeting healthcare providers, hospitals, and pharmaceutical distributors across Asia, the Americas, and other international markets. It offers a comprehensive range of pharmaceutical products under its own brands and through partnerships, supported by strong in-house R&D and advanced global collaborations. The company remains focused on delivering innovative treatments for unmet medical needs while growing its presence in biopharmaceuticals and aesthetic medicine on a global scale. In summary, Daewoong Co., Ltd. is a leading South Korean pharmaceutical company specializing in pharmaceuticals, biologics, biosimilars, stem cell therapies, medical devices, and contract manufacturing services. With a strong emphasis on new drug development and global partnerships, the company has recently expanded into novel therapeutic platforms, Latin American markets, and aesthetic solutions, reinforcing its position as a global healthcare enterprise. It was founded in 1945 and is headquartered in Seongnam, South Korea.